natgillin/translations-raw huggingface dataset:
Animal studies do not indicate harmful effects of emtricitabine, rilpivirine hydrochloride or tenofovir disoproxil on fertility. 
Študije na živalih ne kažejo škodljivih učinkov emtricitabina, rilpivirinijevega klorida ali dizoproksiltenofovirata na plodnost.
Eviplera should be initiated by a physician experienced in the management of HIV infection. 
Zdravljenje z zdravilom Eviplera mora začeti zdravnik, ki že ima izkušnje z zdravljenjem okužbe z virusom HIV.
As rilpivirine is highly bound to plasma proteins, it is unlikely that it will be significantly removed by haemodialysis or peritoneal dialysis (see section 4.9). 
Ker se rilpivirin močno veže na plazemske proteine, je malo verjetno, da ga bo hemodializa ali peritonealna dializa pomembno odstranila (glejte poglavje 4.9).
A large amount of data on pregnant women (more than 1,000 pregnancy outcomes) indicate no malformative nor foetal/neonatal toxicity associated with emtricitabine and tenofovir disoproxil. 
Večje število podatkov pri nosečnicah (več kot 1000 izidov nosečnosti) je pokazalo, da uporaba emtricitabina in dizoproksiltenofovirata ni povzročila nobenih malformacij ali toksičnosti za plod/novorojenčka.
Renal function should be closely monitored (see section 4.4). 
Delovanje ledvic je treba natančno spremljati (glejte poglavje 4.4).
After single dose oral administration of [14C]-rilpivirine, on average 85% and 6.1% of the radioactivity could be retrieved in faeces and urine, respectively. 
Po enojnem peroralnem odmerku [14C rilpivirina se je povprečno 85 % radioaktivnosti izločilo v blatu in 6,1 % v urinu.
In a clinical study rilpivirine did not significantly affect the pharmacokinetics of digoxin. 
V klinični študiji rilpivirin ni pomembno vplival na farmakokinetiko digoksina.
rhabdomyolysis3, 5, muscular weakness3, 5 
rabdomioliza3, 5, mišična oslabelost3, 5
• If you notice after 12 hours or more of the time you usually take Eviplera, then do not take the missed dose. 
• Če opazite po 12 urah ali več od časa, ko običajno vzamete zdravilo Eviplera, pozabljenega odmerka ne vzemite.
• Signs or symptoms of inflammation or infection 
• znaki ali simptomi vnetja ali okužbe
Patients co-infected with HIV and HBV who discontinue Eviplera should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment. 
Bolnike s hkratno HIV in HBV okužbo, ki prekinejo zdravljenje z zdravilom Eviplera, je potrebno pozorneje opazovati in opravljati potrebne klinične in laboratorijske teste še vsaj nekaj mesecev po prenehanju zdravljenja.
A risk for increases in dabigatran plasma concentrations cannot be excluded (inhibition of intestinal P-gp. 
Tveganja za povečanje koncentracij dabigatrana v plazmi ni mogoče izključiti (zaviranje črevesnega P-gp).
The Cmax and AUC for tenofovir increased by 12% and 28% (light meal) and 32% and 38% (standard meal), respectively. 
Cmax tenofovirja se je povečal za 12 % in AUC za 28 % (lahek obrok) oz. za 32 % in 38 % (standardni obrok).
In vitro binding of tenofovir to plasma or serum protein was less than 0.7% and 7.2%, respectively, over the tenofovir concentration range 0.01 to 25 µg/mL. 
In vitro vezava tenofovirja na plazemske proteine je bila manjša od 0,7 % oziroma na serumske proteine manjša od 7,2 % v koncentracijskem območju tenofovirja od 0,01 do 25 µg/ml.
After taking rilpivirine 25 mg once daily as part of an antiretroviral regimen, the total exposure of rilpivirine was lower during pregnancy (similar for the 2nd and 3rd trimester) compared with postpartum. 
Po jemanju rilpivirina 25 mg enkrat dnevno kot del protiretrovirusnega režima je bila skupna izpostavljenost rilpivirinu v nosečnosti (podobna v 2. in 3. trimesečju) nižja v primerjavi s poporodnim obdobjem.
Pharmacokinetic parameters were mainly determined following administration of single doses of emtricitabine 200 mg or tenofovir disoproxil 245 mg to non-HIV infected patients with varying degrees of renal impairment. 
Farmakokinetične parametre so v glavnem določili po vzetju enkratnih odmerkov 200 mg emtricitabina ali 245 mg dizoproksiltenofovirata pri bolnikih, ki niso bili okuženi s HIV, z različnimi stopnjami ledvične okvare.
The Cmax and AUC of rilpivirine increased by 34% and 9% (light meal) and 26% and 16% (standard meal), respectively. 
Cmax rilpivirina se je povečal za 34 % in AUC za 9 % (lahek obrok) oz. za 26 % in 16 % (standardni obrok).
After week 24, the HIV-1 from 2 additional patients in the Eviplera arm developed resistance by week 48 (total of 4 of 469 patients, 0.9%). 
Po 24. tednu se je pri HIV-1 pri 2 dodatnih bolnikih v kraku z zdravilom Eviplera razvila rezistenca do 48. tedna (skupaj 4 od 469 bolnikov, 0,9 %).
Rilpivirine (taken as Eviplera in 16 of 19 patients and another background regimen in 3 of 19 patients) was evaluated in study TMC114HIV3015 in pregnant women during the 2nd and 3rd trimesters, and postpartum. 
Rilpivirin (v obliki zdravila Eviplera pri 16 od 19 bolnikov in druge osnovne sheme zdravljenja pri 3 od 19 bolnikov) je bil ocenjen v študiji TMC114HIV3015 pri nosečnicah med 2. in 3. trimesečjem in po porodu.
These symptoms resolved after Eviplera was discontinued. 
Ti simptomi so po prekinitvi jemanja zdravila Eviplera izzveneli.
The pharmacokinetics of rilpivirine and tenofovir disoproxil in children and adolescents are under investigation. 
Farmakokinetika rilpivirina in dizoproksiltenofovirata pri otrocih in mladostnikih se preučuje.
The mean baseline CD4 cell count was 584 x 106 cells/L (range 42-1,484). 
Povprečno število celic CD4 na začetku je bilo 584 x 106 celic/l (razpon 42-1.484).
Since rilpivirine is highly protein bound, dialysis is unlikely to result in significant removal of the active substance. 
Ker se rilpivirin močno veže na beljakovine, ni verjetno, da bi dializa značilno odstranila učinkovino.
Each film-coated tablet contains 277 mg lactose monohydrate and 4 micrograms sunset yellow aluminium lake (E110). 
Vsaka filmsko obložena tableta vsebuje 277 mg laktoze monohidrata in 4 mikrograme barvila sončno rumeno FCF (E110).
There is limited information available on the potential for a pharmacodynamic interaction between rilpivirine and medicinal products that prolong the QTc interval of the electrocardiogram. 
Podatki o možnem farmakodinamičnem medsebojnem delovanju med rilpivirinom in zdravili, ki podaljšujejo interval QTc na elektrokardiogramu, je malo.
Discontinued study drug due to other reasons and last available HIV-1 RNA < 50 copies/mLe 
Prekinitev uporabe študijskega zdravila zaradi drugih razlogov in nazadnje razpoložljivi HIV-1 RNA < 50 kopij/mle
• antacids (aluminium/magnesium hydroxide or calcium carbonate) 
• antacidi (aluminijev/magnezijev hidroksid ali kalcijev karbonat)
Randomisation was stratified by use of tenofovir disoproxil and/or lopinavir/ritonavir in the baseline regimen. 
Randomizacija je bila stratificirana z uporabo dizoproksiltenofovirata in/ali lopinavirja/ritonavirja v začetnem režimu.
Among 49 patients who received at least one dose of Eviplera, 100% of patients remained suppressed (HIV-1 RNA < 50 copies/mL) at week 12 and week 24. 
ki so prejeli vsaj en odmerek zdravila Eviplera, je 100 % bolnikov ohranilo supresijo (HIV-1 RNA < 50 kopij/ml) v 12. tednu in v 24. tednu.
4 The predominant circulating metabolite of sofosbuvir. 
4 Prevladujoči presnovek sofosbuvirja v obtoku.
As a result, the amounts of Eviplera or other medicines in your blood may be affected. 
To lahko posledično vpliva na količino zdravila Eviplera ali drugih zdravil v vaši krvi.
Overall response (HIV-1 RNA < 50 copies/mL (TLOVRa))b 
Celokupni odziv (HIV-1 RNA < 50 kopij/ml (TLOVRa))b
What Eviplera is and what it is used for What you need to know before you take Eviplera How to take Eviplera 
Kaj je zdravilo Eviplera in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Eviplera Kako jemati zdravilo Eviplera Možni neželeni učinki
It is important not to miss a dose of Eviplera. 
Pomembno je, da ne pozabite vzeti nobenega odmerka zdravila Eviplera.
Switching to Eviplera was non-inferior in maintaining HIV-1 RNA < 50 copies/mL when compared to patients who stayed on a ritonavir-boosted PI in combination with two NRTIs [treatment difference (95% CI): + 3.8% (-1.6% to 9.1%)]. 
Prehod na zdravilo Eviplera ni bil slabši pri ohranjanju HIV-1 RNA < 50 kopij/ml v primerjavi z bolniki, ki so ostali na zdravljenju s PI, okrepljenim z ritonavirjem, v kombinaciji z dvema NRTI [razlika zdravljenja (95-% IZ): + 3,8 % (−1,6 % do 9,1 %)].
• Other allergic reactions, such as wheezing, swelling or feeling light-headed 
• druge alergijske reakcije, kot so piskanje, otekanje ali omotičnost
Nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs/N[t]RTIs) Didanosine/Emtricitabine 
Nukleozidni ali nukleotidni zaviralci reverzne transkriptaze (NRTI/N[t]RTI) didanozin/emtricitabin
As Eviplera may cause renal damage, monitoring of renal function is recommended (see sections 4.4 and 4.8, Summary of the safety profile). 
Ker lahko zdravilo Eviplera povzroči ledvično poškodbo, se priporoča nadziranje ledvične funkcije (glejte poglavji 4.4 in 4.8 Povzetek varnostnega profila).
• Anaemia (low red blood cell count) 
• anemija (nizko število rdečih krvnih telesc)
The median change in CD4+ cell count at week 48 was +17 x 106 cells/L, in the on-treatment analysis. 
Mediana sprememba v številu celic CD4 v 48. tednu je bila +17 x 106 celic/l v analizi med zdravljenjem.
Resistance to rilpivirine2 Cross-resistance3 to etravirine efavirenz nevirapine 
Rezistenca na rilpivirin1 Navzkrižna rezistenca2 na etravirin efavirenz nevirapin
• Medicines for stomach ulcers, heartburn or acid reflux such as: 
• Zdravila za zdravljenje razjed, zgage ali refluksa kisline, kot so:
In another study, the Y188L substitution resulted in a reduced susceptibility to rilpivirine of 9-fold for clinical isolates and 6-fold for site-directed mutants. 
V drugi študiji je substitucija Y188L povzročila 9-krat manjšo občutljivost kliničnih izolatov in 6-krat manjšo občutljivost lokacijsko usmerjenih mutantov na rilpivirin.
Patients were switched from efavirenz/emtricitabine/tenofovir disoproxil to Eviplera without a washout period. 
Bolniki so prešli z zdravljenja z efavirenzom/ emtricitabinom/dizoproksiltenofoviratom na zdravilo Eviplera brez obdobja izpiranja.
• foscarnet, ganciclovir, cidofovir (for viral infections) 
• foskarnet, ganciklovir, cidofovir (za virusne okužbe)
Lower exposures of rilpivirine were observed during pregnancy; therefore viral load should be monitored closely. 
Med nosečnostjo so opazili nižje izpostavljenosti rilpivirinu, zato je treba skrbno spremljati virusno obremenitev.
In a 144-week controlled clinical study that compared tenofovir disoproxil with stavudine in combination with lamivudine and efavirenz in antiretroviral-naïve patients, small decreases in BMD of the hip and spine were observed in both treatment groups. 
V 144 tednov trajajoči kontrolirani klinični študiji, v kateri sta bila primerjana dizoproksiltenofovirat in stavudin v kombinaciji z lamivudinom in efavirenzom pri bolnikih, ki še niso bili zdravljeni s protiretrovirusnimi zdravili, so pri obeh zdravljenih skupinah opazili manjše zmanjšanje BMD kolka in hrbtenice.
In study C215 (n = 678), the BR consisted of 2 investigator selected N(t)RTIs: emtricitabine/tenofovir disoproxil (60%, n = 406) or lamivudine/zidovudine (30%, n = 204) or abacavir plus lamivudine (10%, n = 68). 
V študiji C215 (n = 678) je bil BR sestavljen iz 2 N(t)RTI-jev, ki ju je izbral raziskovalec: emtricitabin/dizoproksiltenofovirat (60 %, n = 406) ali lamivudin/zidovudin (30 %, n = 204) ali abakavir in lamivudin (10 %, n = 68).
The effect of rilpivirine hydrochloride at the recommended dose of 25 mg once daily on the QTcF interval was evaluated in a randomised, placebo and active (moxifloxacin 400 mg once daily) controlled crossover study in 60 healthy adults, with 13 measurements over 24 hours at steady-state. 
Učinek rilpivirinijevega klorida pri priporočenem odmerku 25 mg enkrat dnevno na interval QTcF je bil ocenjen v randomizirani, s placebom in aktivno (moksifloksacin 400 mg enkrat dnevno) kontrolirani navzkrižni študiji s 60 zdravimi odraslimi, s 13 meritvami v 24 urah v stanju dinamičnega ravnovesja.
Eviplera has not been studied in patients over the age of 65 years. 
Zdravila Eviplera niso proučevali pri bolnikih, starejših od 65 let.
In some patients with advanced liver disease or cirrhosis, stopping treatment is not recommended as this may lead to worsening of your hepatitis, which may be lifethreatening. 
Pri nekaterih bolnikih z napredovalim obolenjem jeter ali cirozo prenehanje zdravljenja ni priporočeno, saj lahko to povzroči poslabšanje hepatitisa, ki je lahko življenjsko nevarno.
Rilpivirine-resistant strains were selected in cell culture starting from wild-type HIV-1 of different origins and subtypes as well as NNRTI-resistant HIV-1. 
V celični kulturi so bili izbrani na rilpivirin rezistentni sevi, od divjega tipa virusa HIV-1 različnih izvorov in podtipov ter proti NNRTI rezistenten virus HIV-1.
Co-administration of tenofovir disoproxil and didanosine at a dose of 400 mg daily has been associated with a significant decrease in CD4+ cell count, possibly due to an intracellular interaction increasing phosphorylated (i.e. active) didanosine. 
Sočasna uporaba dizoproksiltenofovirata in didanozina pri odmerku 400 mg dnevno je bila povezana s pomembnim zmanjšanjem števila celic CD4+, morda zaradi znotrajceličnih interakcij, ki so povečale količino fosforiliranega (to je aktivnega) didanozina.
P-glycoprotein substrates 
Substrati P-glikoproteina
Rilpivirine exhibited activity against laboratory strains of wild-type HIV-1 in an acutely infected T-cell line with a median EC50 value for HIV-1/IIIB of 0.73 nM (0.27 ng/mL). 
Rilpivirin je pokazal aktivnost proti laboratorijskim sevom divjega tipa HIV-1 v akutno okuženi liniji T-celic z mediano vrednostjo EC50 za virus HIV-1/IIIB 0,73 nM (0,27 ng/ml).
Genotoxicity and repeated dose toxicity studies of one month or less with the combination of emtricitabine and tenofovir disproxil found no exacerbation of toxicological effects compared to studies with the separate components. 
V študijah genotoksičnosti in študijah toksičnosti s ponavljajočim se odmerkom, ki so trajale en mesec ali manj z uporabo kombinacije emtricitabina in dizoproksiltenofovirata niso ugotovili poslabšanja toksikoloških vplivov, v primerjavi s posameznima učinkovinama.
If you vomit less than 4 hours after taking Eviplera, take another tablet with food. 
Če bruhate manj kot 4 ure po zaužitju zdravila Eviplera, vzemite še eno tableto s hrano.
Purplish-pink, capsule-shaped, film-coated tablet of dimensions 19 mm x 8.5 mm, debossed on one side with “GSI” and plain on the other side. 
Vijolično-rožnata filmsko obložena tableta v obliki kapsule z dimenzijami 19 mm x 8,5 mm, z vtisnjenim znakom “GSI” na eni strani in prazna na drugi strani.
Rilpivirine activity is mediated by non-competitive inhibition of HIV-1 reverse transcriptase (RT). 
Aktivnost rilpivirina poteka s pomočjo nekompetitivnega zaviranja reverzne transkriptaze (RT) HIV-1.
Decreases in BMD of spine and changes in bone biomarkers from baseline were significantly greater in the tenofovir disoproxil treatment group at 144 weeks. 
Zmanjšanje mineralne gostote kosti hrbtenice in spremembe kostnih biomarkerjev od začetne vrednosti so bile v 144 tednih pomembno večje v skupini, ki se je zdravila z dizoproksiltenofoviratom.
Up to 30% of the emtricitabine dose and approximately 10% of the tenofovir dose can be removed by haemodialysis. 
Specifičnega antidota za preveliko odmerjanje zdravila Eviplera ni. Do 30 % odmerka emtricitabina in približno 10 % odmerka tenofovirja se lahko odstrani s hemodializo.
Women of childbearing potential / contraception in males and females The use of Eviplera must be accompanied by the use of effective contraception. 
Ženske v rodni dobi/uporaba kontracepcije pri moških in ženskah Pri uporabi zdravila Eviplera je treba uporabljati učinkovito kontracepcijo.
The mutations associated with NRTI resistance that developed in 3 or more patients were: K65R, K70E, M184V/I and K219E during the treatment period. 
Mutacije, povezane z rezistenco na NRTI, ki so se razvile pri 3 ali več bolnikih, so bile: K65R, K70E, M184V/I in K219E v obdobju zdravljenja.
The usual dose is one tablet taken each day by mouth. 
Običajen odmerek je ena tableta peroralno vsak dan. Tableto morate vzeti vsak dan s hrano.
• amphotericin B, pentamidine (for fungal infections) 
• amfotericin B, pentamidin (za glivične okužbe)
At week 48, 89% (283/317) of patients randomised to switch to Eviplera at baseline (Eviplera) had HIV-1 RNA < 50 copies/mL, 3% (8/317) were considered virologic failures (HIV RNA ≥ 50 copies/mL), and 8% (26/317) did not have data available in the week 48 window. 
V 48. tednu je imelo 89 % (283/317) bolnikov, randomiziranih za prehod na zdravilo Eviplera na začetku (Eviplera), HIV-1 RNA < 50 kopij/ml, 3 % (8/317) so bili obravnavani kot virološki neuspehi (HIV RNA ≥ 50 kopij/ml) in za 8 % (26/317) v oknu 48. tedna ni bilo razpoložljivih podatkov.
• Increases in creatinine in your blood 
• povišan kreatinin v krvi
Resistance to emtricitabine or tenofovir has been seen in vitro and in some HIV-1 infected patients due to the development of the M184V or M184I substitution in RT with emtricitabine, or the K65R substitution in RT with tenofovir. 
Rezistenca na emtricitabin ali tenofovir je bila opažena in vitro in pri nekaterih bolnikih, okuženih s HIV-1, zaradi razvoja substitucije M184V ali M184I na RT pri emtricitabinu ali substituciji K65R na RT pri tenofovirju.
Only H2-receptor antagonists that can be dosed once daily should be used. 
Uporabljajte samo receptorje H2, ki jih je mogoče odmerjati enkrat dnevno.
There was no difference in the change from baseline in whole body BMD or BMC for rilpivirine compared with control, in the overall population or in those patients treated with a backbone regimen including tenofovir disoproxil. 
Razlike v spremembi od začetne vrednosti BMD ali BMC za rilpivirin v primerjavi s kontrolno skupino, splošno populacijo ali bolniki z osnovno shemo zdravljenja, vključno z dizoproksiltenofoviratom, ni bilo.
If you accidentally take more than the recommended dose of Eviplera you may be at increased risk of experiencing possible side effects with this medicine (see section 4, Possible side effects). 
Če ste pomotoma zaužili odmerek zdravila Eviplera, višji od priporočenega, obstaja povečano tveganje za pojav možnih neželenih učinkov (glejte poglavje 4, Možni neželeni učinki).
In women receiving rilpivirine 25 mg once daily during the 2nd trimester of pregnancy, mean intraindividual values for total rilpivirine Cmax, AUC24h and Cmin values were 21%, 29% and 35% lower, respectively, as compared to postpartum; during the 3rd trimester of pregnancy, Cmax, AUC24h and Cmin values were 20%, 31% and 42% lower, respectively, as compared to postpartum. 
Pri ženskah, ki so prejemale 25 mg rilpivirina enkrat dnevno med 2. trimesečjem nosečnosti, so bile srednje vrednosti med posameznicami za vrednosti celokupnega rilpivirina Cmax, AUC24h in Cmin v primerjavi s poporodnim obdobjem nižje za 21 %, 29 % in 35 %; med 3. trimesečjem nosečnosti pa so bile vrednosti Cmax, AUC24h in Cmin v primerjavi s poporodnim obdobjem nižje za 20 %, 31 % in
Eviplera may affect your kidneys. 
Zdravilo Eviplera lahko vpliva na ledvice.
Adverse reaction Blood and lymphatic system disorders 
Bolezni krvi in limfatičnega sistema
Viruses harbouring substitutions conferring reduced susceptibility to stavudine and zidovudine-thymidine analogue-associated mutations-TAMs (M41L, D67N, K70R, L210W, T215Y/F, K219Q/E), or didanosine (L74V) remained sensitive to emtricitabine. 
Virusi s substitucijami, ki so pomenile zmanjšano občutljivost na TAM-e (mutacijske povezane z analogi stavudina in zidovudin-timidina, npr. M41L, D67N, K70R, L210W, T215Y/F, K219Q/E) ali didanozin (L74V) so ostali občutljivi na emtricitabin.
There is insufficient information on the effects of Eviplera in newborns/infants. 
Podatki o učinku zdravila Eviplera na dojene novorojence/otroke so nezadostni.
Emtricitabine/tenofovir disoproxil + rilpivirine hydrochloride has been shown to be non-inferior in achieving HIV-1 RNA < 50 copies/mL compared to emtricitabine/tenofovir disoproxil + efavirenz. 
Pokazalo se je, da emtricitabin/dizoproksiltenofovirat + rilpivirinijevim kloridom nista slabša pri doseganju HIV-1 RNA < 50 kopij/ml v primerjavi z emtricitabinom/dizoproksiltenofoviratom + efavirenzom.
The degree of renal impairment was defined according to baseline CrCl (normal renal function when CrCl > 80 mL/min; mild impairment with CrCl = 50-79 mL/min; moderate impairment with CrCl = 30-49 mL/min and severe impairment with CrCl = 10-29 mL/min). 
Stopnja ledvične okvare je bila določena glede na začetno vrednost CrCl (normalna ledvična funkcija je pri CrCl > 80 ml/min; blaga ledvična okvara pri CrCl = 50-79 ml/min; zmerna ledvična okvara pri CrCl = 30-49 ml/min in huda ledvična okvara pri CrCl = 10-29 ml/min).
Once you start taking Eviplera, look out for: 
Med jemanjem zdravila Eviplera Ko začnete jemati zdravilo Eviplera, bodite pozorni na:
It was also identified as an adverse reaction for emtricitabine through post-marketing surveillance but was not observed in randomised controlled clinical studies in adults or paediatric HIV clinical studies of emtricitabine. 
Opredeljen je bil tudi kot neželeni učinek emtricitabina v okviru nadzora v obdobju trženja, niso pa ga zabeležili v razdomiziranih kontroliranih kliničnih študijah pri odraslih ali pediatričnih bolnikih z okužbo z virusom HIV.
The following pack sizes are available: outer cartons containing 1 bottle of 30 film-coated tablets and outer cartons containing 90 (3 bottles of 30) film-coated tablets. 
Na voljo so naslednje velikosti pakiranj: škatle s po 1 plastenko s 30 filmsko obloženimi tabletami in škatle z 90 (3 plastenke s po 30) filmsko obloženimi tabletami.
After oral administration of the single components emtricitabine and tenofovir disoproxil, emtricitabine and tenofovir are widely distributed throughout the body. 
Po peroralnem vnosu posamezne sestavine emtricitabina in dizoproksiltenofovirata sta emtricitabin in tenofovir v telesu široko distribuirana.
Sex Male Female Ethnicity White Black/African American Asian Other Not allowed to ask per local regulations Baseline disease characteristics Median baseline plasma HIV-1 RNA (range), log10 copies/mL Median baseline CD4+ cell count (range), x 106 cells/L Percentage of patients with HBV/HCV co-infection 
Spol Moški Ženski Etničnost Belci Črnci/afriški Američani Azijci Drugo Ni dovoljeno vprašati v skladu z lokalno zakonodajo Začetne značilnosti bolezni Mediana začetna vrednost HIV-1 RNA (razpon) log10 kopij/ml v plazmi Mediana začetna vrednost CD4+ število celic (razpon), × 106 celic/l Odstotek bolnikov s sočasno okužbo s HBV/HCV
Emtricitabine exposures were not affected by food. 
Hrana ni vplivala na izpostavljenost emtricitabinu.
Through week 48, no emergent resistance developed in the 2 patients who failed virologically among patients who switched to Eviplera from efavirenz/emtricitabine/tenofovir disoproxil (0 of 49 patients). 
Do konca 48. tedna se rezistenca, nastala med zdravljenjem, ni razvila pri 2 bolnikih, ki sta imela virološki neuspeh, med bolniki, ki so prešli na zdravljenje z zdravilom Eviplera z efavirenza/emtricitabina/dizoproksiltenofovirja (0 od 49 bolnikov).
H2-antagonists should not be taken in a twice a day regimen. 
Antagonistov H2 ne jemljite z režimom dvakrat dnevno.
Contains lactose monohydrate and sunset yellow aluminium lake (E110), see leaflet for further information. 
Vsebuje laktozo monohidrat in barvilo sončno rumeno FCF (E110), za dodatne informacije glejte navodilo za uporabo.
High density polyethylene (HDPE) bottle with a polypropylene child-resistant closure containing 30 film-coated tablets and a silica gel desiccant. 
Plastenka iz polietilena visoke gostote (HDPE), s polipropilensko, za otroke varno zaporko, ki vsebuje 30 filmsko obloženih tablet in silikagelsko sušilno sredstvo.
CCR5 antagonists Maraviroc/Emtricitabine 
Antagonisti CCR5 maravirok/emtricitabin